SIGYN THERAPEUTICS INC | 10-Q: Quarterly report
Presenting on the Emerging Growth Conference 70 Day 2 on May 9 Register Now
Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now
Sigyn Therapeutics Announces Reverse Stock Split
SAN DIEGO, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a development-stage medical technology company, today announced that a 1-for-40
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
SAN DIEGO, CA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a development-stage medical technology company, today announced the appointment of
Sigyn Therapeutics Inc GAAP EPS of -$0.02
Sigyn Therapeutics Reports Third Quarter 2023 Financial Results
SAN DIEGO, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a development-stage medical technology company, today announces financial results for
Sigyn Therapeutics Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrep Trademark Application
SAN DIEGO, CA, May 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB:SIGY), a development-stage medical technology company, disclosed today that it has
Sigyn Therapeutics, Inc. GAAP EPS of -$0.03
Sigyn Therapeutics, Inc. GAAP EPS of -$0.02
Sigyn Therapeutics, Inc. press release (OTCQB:SIGY): Q2 GAAP EPS of -$0.02. Second quarter 2022 net cash used in operating activities was approximately $395,000.
Signy Therapeutics names new CFO
Signy Therapeutics (OTCPK:SIGY) has announced the appointment of CPA Jeremy Ferrell as the company's new chief financial officer, effective Mar. 9, 2022. The company told Ferrell brings in over 25 yea
Sigyn Therapeutics™ Appoints Accomplished Financial Executive, Jeremy Ferrell, as Chief Financial Officer
SAN DIEGO, CA, March 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets:"SIGY"), a medical technology company focused on the treatment of pathogen-associated condi
No Data